Relatlimab-nivolumab: A practical overview for dermatologists.

Area of Science:

• Immunotherapy
• Oncology
• Dermatology

Background:

• Relatlimab is a novel antibody targeting lymphocyte-activation gene 3 (LAG-3).
• It is approved in combination with nivolumab, a programmed cell death protein 1 (PD-1) inhibitor.
• This combination targets two key immune checkpoints for cancer treatment.

Purpose of the Study:

• To review the clinical literature on the efficacy and therapeutic use of relatlimab-nivolumab.
• To summarize the mechanism of action, clinical efficacy, and safety profile.
• To highlight ongoing clinical trials and areas of active investigation.

Main Methods:

• Literature review of recent publications.
• Analysis of clinical trial data.
• Overview of immune checkpoint inhibition mechanisms.

Main Results:

• Relatlimab-nivolumab demonstrates efficacy in metastatic melanoma.
• The combination offers a dual checkpoint blockade.
• Safety profile of the combination is established.

Conclusions:

• Relatlimab-nivolumab is an approved first-line dual checkpoint inhibitor for metastatic melanoma.
• This review informs dermatologists on its appropriate clinical use.
• It represents a significant advancement in melanoma treatment.